Form 4: Vertex Pharma Exec Acquires RSUs, Sells Shares

Vertex Pharmaceuticals EVP Ourania Tatsis acquired restricted stock units and sold common stock shares under a Rule 10b5-1 plan.

Summary

• EVP, Chief Regulatory & Quality Officer Ourania Tatsis acquired 5,789 shares of Vertex Pharmaceuticals common stock as a restricted stock unit award on February 17, 2026.
• These restricted stock units will vest in installments beginning on February 20, 2027.
• Tatsis disposed of 2,294 shares of common stock on February 17, 2026, at a price of $483.75 per share, likely for tax withholding purposes.
• Additionally, Tatsis sold 609 shares of common stock on February 17, 2026, at $489.46 per share.
• Another 368 shares of common stock were sold on February 18, 2026, at $473.68 per share.
• All sales were conducted pursuant to a Rule 10b5-1 trading plan established on August 21, 2025.
• Following these transactions, Tatsis beneficially owns 48,650 shares of common stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. The acquisition of RSUs aligns executive interests with shareholders, while the sales are routine under a 10b5-1 plan and include tax-related dispositions.

Positives

• Acquisition of 5,789 restricted stock units by a key executive, indicating continued alignment of interests with shareholders.

Negatives

• Sale of 977 shares of common stock (609 + 368) by a key executive, which could be perceived as a reduction in direct ownership.
• Disposition of 2,294 shares for tax withholding, a common practice but still a reduction in direct holdings.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider transactions, particularly those executed under pre-arranged Rule 10b5-1 plans, are common in the pharmaceutical industry as a mechanism for executives to manage their personal portfolios while complying with insider trading regulations. The combination of RSU awards and subsequent sales for tax purposes and portfolio diversification is a standard practice.

Stakeholder Impact

• Shareholders: The acquisition of restricted stock units by a key executive aligns her interests with long-term shareholder value, while the sales are routine and not indicative of a change in company fundamentals.

Next Steps

• Restricted stock units will begin vesting in installments starting February 20, 2027.

Key Dates

Recommendation

The filing details routine insider transactions, including the grant of restricted stock units and sales under a pre-arranged 10b5-1 plan. These transactions are typical for executive compensation and personal financial management and do not provide new fundamental information to warrant a change in investment recommendation. The net effect of acquiring RSUs and selling some shares is largely neutral for the company's outlook.

Keywords

Vertex Pharmaceuticals, VRTX, Insider Trading, Form 4, Restricted Stock Units, Stock Sale, Executive Compensation, Rule 10b5-1